WORCESTER, Mass.–(BUSINESS WIRE)–First paragraph, second sentence of release should read: Juniper advanced through the program, previously winning both the Phase 1 and Phase 2 Neuromod Prizes, bringing the total cash awarded to $2.9 million. (instead of Juniper advanced through the program, previously winning both the Phase 1 and Phase 2 Neuromod Prizes, bringing the total cash awarded to $2.7 million.)
The updated release reads:
JUNIPER BIOMEDICAL WINS NEUROMOD PRIZE AND WELCOMES FRANK FISCHER TO BOARD OF DIRECTORS
Juniper Biomedical, a medical device company developing solutions to treat pelvic health disorders using their unique neuromodulation micro-implant, announced today that the company won the Phase 3 of the prestigious NIH SPARC Neuromod Prize, which included a $1.6 million cash award. Juniper advanced through the program, previously winning both the Phase 1 and Phase 2 Neuromod Prizes, bringing the total cash awarded to $2.9 million. These funds support the continued product development and clinical trials of the company’s first solution, a long-term precision therapy for individuals experiencing mixed urinary incontinence (MUI), which affects nearly 1 in 4 women.
MUI is the combination of Stress Urinary Incontinence (SUI) and Urge Urinary Incontinence (UUI) and there is currently no advanced solution in the market that treats both symptoms of MUI.
The Company also announced that Frank Fischer, founder and chairman of the board of Neuropace and medtech serial entrepreneur, recently joined the Juniper Board of Directors.
“We are honored to welcome Frank Fischer to our Board of Directors. Frank’s extensive leadership experience and successful track record creating new medical device categories in cardiology and neurology will be invaluable to Juniper as we pioneer innovative neuromodulation therapies for pelvic health disorders,” said David Constantine, co-founder and CEO of Juniper Biomedical. “The Neuromod Prize has been a profound accelerant to the core translational effort required to bring Juniper’s innovation to the millions of patients suffering with inadequate solutions. Receiving this Phase 3 final award is a tremendous honor and a testament to the work of our deeply committed team.”
Mr. Fischer has served as the Chairman of the Board of Directors of Neuropace since 2019. Previously, he was President and Chief Executive Officer from 2000 to July of 2019. Prior to that, Mr. Fischer was President and CEO of Heartport, Inc., a medical device company, from 1998 to 1999, and served on Heartport’s board of directors from 1992 to 1999. Previously, he was President and CEO of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, which was sold to St. Jude Medical, Inc. in 1997.
“I’m pleased to join Juniper Biomedical’s Board of Directors. I’m impressed by the executive team and the company’s technology platform and am confident that Juniper has what it takes to bring to market its game-changing precision neuromodulation technology to address the unmet need for less invasive, effective, and safe therapies for pelvic health disorders,” said Frank Fischer.
About the Neuromod Prize
The Neuromod Prize is a SPARC initiative from the National Institutes of Health (NIH). SPARC — Stimulating Peripheral Activity to Relieve Conditions — is an NIH Common Fund program that’s advancing the science of neuromodulation. SPARC’s mission is to catalyze the development of next-generation therapies that target the peripheral nervous system, and to bring together innovators from across disciplines to translate discoveries into treatments that improve patients’ lives.
About Juniper Biomedical
Juniper Biomedical is developing dramatically better therapies for the millions individuals suffering from pelvic health conditions including urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders. Our solutions leverage a highly precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves.
Contacts
Helen Shik
Shik Communications
[email protected]
